BioAge Labs, Inc. - Common Stock (BIOA)
4.6300
+0.2600 (5.95%)
BioAge Labs is a biotechnology company focused on leveraging artificial intelligence and machine learning to unlock the biology of aging and develop therapeutics that can extend healthy lifespan
The company harnesses its proprietary platform to analyze vast amounts of biological data in order to identify and validate novel drug targets linked to aging-related diseases. Through its innovative research, BioAge aims to create effective therapies that not only treat age-associated conditions but also improve overall health and longevity in individuals.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · February 28, 2025
RADNOR, PA - February 28, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against BioAge Labs, Inc. (“BioAge”) (NASDAQBIOA) on behalf of those who purchased stock pursuant and/or traceable to BioAge's registration statement for its initial public offering (“IPO”) held on or about September 26, 2024 (the “Class Period”). The lead plaintiff deadline is March 10, 2025.
Via TheNewswire.com · February 28, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · February 26, 2025
RADNOR, PA - February 26, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against BioAge Labs, Inc. (“BioAge”) (NASDAQBIOA) on behalf of those who purchased stock pursuant and/or traceable to BioAge's registration statement for its initial public offering (“IPO”) held on or about September 26, 2024 (the “Class Period”). The lead plaintiff deadline is March 10, 2025.
Via TheNewswire.com · February 26, 2025

The law firm of Kirby McInerney LLP notifies investors of the approaching March 10, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of those who acquired BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQBIOA) securities from September 22, 2024, through January 7, 2025 (“the Class Period”).
By Kirby McInerney LLP · Via Business Wire · February 25, 2025

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
By Bernstein Liebhard LLP · Via GlobeNewswire · February 25, 2025

NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of BioAge Labs, Inc. (NASDAQBIOA), Nextracker Inc. NASDAQ:NXTNASDAQNXT)(NASDAQ:FTAINASDAQFTAI, and Revance Therapeutics, Inc. (NASDAQ:RVNCNASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · February 24, 2025

The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against BioAge Labs, Inc. (“BioAge”) (NASDAQBIOA) on behalf of those who purchased stock pursuant and/or traceable to BioAge's registration statement for its initial public offering (“IPO”) held on or about September 26, 2024 (the “Class Period”). The lead plaintiff deadline is March 10, 2025.
By Kessler Topaz Meltzer & Check, LLP · Via Business Wire · February 24, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · February 24, 2025
RADNOR, PA - February 24, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against BioAge Labs, Inc. (“BioAge”) (NASDAQBIOA) on behalf of those who purchased stock pursuant and/or traceable to BioAge's registration statement for its initial public offering (“IPO”) held on or about September 26, 2024 (the “Class Period”). The lead plaintiff deadline is March 10, 2025.
Via TheNewswire.com · February 24, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · February 23, 2025
RADNOR, PA - February 23, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against BioAge Labs, Inc. (“BioAge”) (NASDAQBIOA) on behalf of those who purchased stock pursuant and/or traceable to BioAge's registration statement for its initial public offering (“IPO”) held on or about September 26, 2024 (the “Class Period”). The lead plaintiff deadline is March 10, 2025.
Via TheNewswire.com · February 23, 2025

NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · February 20, 2025

RICHMOND, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in one-on-one meetings at TD Cowen's 45th Annual Health Care Conference.
By BioAge Labs, Inc. · Via GlobeNewswire · February 20, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · February 20, 2025
RADNOR, PA - February 20, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against BioAge Labs, Inc. (“BioAge”) (NASDAQBIOA) on behalf of those who purchased stock pursuant and/or traceable to BioAge's registration statement for its initial public offering (“IPO”) held on or about September 26, 2024 (the “Class Period”). The lead plaintiff deadline is March 10, 2025.
Via TheNewswire.com · February 20, 2025

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In BioAge To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · February 19, 2025

SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all shareholders who purchased stock pursuant and/or traceable to the BioAge Labs, Inc. (NASDAQBIOA) registration statement for the initial public offering (IPO) held on September 26, 2024. BioAge claims it is a "clinical stage biopharmaceutical company” that develops therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging.
By Robbins LLP · Via GlobeNewswire · February 18, 2025

The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQBIOA) securities during the period from September 22, 2024, through January 7, 2025 (“the Class Period”). Investors have until March 10, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
By Kirby McInerney LLP · Via Business Wire · February 18, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · February 18, 2025
RADNOR, PA - February 18, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against BioAge Labs, Inc. (“BioAge”) (NASDAQBIOA) on behalf of those who purchased stock pursuant and/or traceable to BioAge's registration statement for its initial public offering (“IPO”) held on or about September 26, 2024 (the “Class Period”). The lead plaintiff deadline is March 10, 2025.
Via TheNewswire.com · February 18, 2025

NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · February 17, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · February 16, 2025
RADNOR, PA - February 16, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against BioAge Labs, Inc. (“BioAge”) (NASDAQBIOA) on behalf of those who purchased stock pursuant and/or traceable to BioAge's registration statement for its initial public offering (“IPO”) held on or about September 26, 2024 (the “Class Period”). The lead plaintiff deadline is March 10, 2025.
Via TheNewswire.com · February 16, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · February 14, 2025